Brorphine

"Brorphine and its piperidyl benzimidazolone analogues represent an emerging class of synthetic opioids, generally characterized by potent MOR [Mu-Opioid Recepter] agonism, significant analgesic activity, and substantial toxicological risk. Although originally developed in the search for safer, G protein–biased analgesics, their pharmacological profile, and preclinical data suggest high abuse potential, respiratory depression, and dependence liability comparable to classical opioids.

"Although several nonfatal and fatal intoxications have been reported exclusively in connection with brorphine, the potential danger associated with its analogues should not be underestimated. These compounds share structural similarities and may exhibit comparable or even enhanced potency, raising significant concerns regarding their toxicological impact. The identification of brorphine in multiple intoxication cases underscores the substantial risks posed by this emerging class of synthetic opioids and highlights the urgent need for strict monitoring through early-warning systems and strengthened toxicological surveillance. Moreover, the continuous emergence of new analogues further complicates detection and risk assessment. Despite recent progress in analytical methodologies, significant gaps persist: validated reference materials and standardized workflows remain lacking, limiting laboratories' ability to reliably identify and quantify these substances."